AGC Biologics A/S: Financial statements 2013
CVR: 25950941
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
AGC Biologics A/S (CVR 25950941) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK 37,248,000 and a net result of DKK -128,000. Equity in the 2013 report amounted to DKK 136,341,000. The solvency ratio was 43.8%. The company had 185 employees in the financial year.
- Gross Profit
- DKK 37,248,000
- Profit/Loss
- DKK -128,000
- Equity
- DKK 136,341,000
- Total Assets
- DKK 311,339,000
- Employees
- 185
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
As of November 1, 2013, Douglas Robert Sanders has stepped down as director of AGC Biologics A/S.
AGC Biologics A/S has published its annual report for 2012.
About AGC Biologics A/S
AGC Biologics A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 2001. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named CMC BIOLOGICS A/S and CMC BIOPHARMACEUTICALS A/S. The management consists of Kasper Møller. The board consists of Tadashi Murano (chair), Alberto Santagostino, Kasper Møller and Mai Iwaya. The company is owned by Asahi Glass Co., Ltd.. The company has 1,503 employees (2026). In 2025, the company reported revenue of DKK 1,959,639,000 and a net result of DKK -328,010,000 compared with DKK -115,005,000 the year before. Equity in the 2025 report amounted to DKK 312,021,000.
